Dr Brufsky on Unmet Needs and Unanswered Questions in HR+/HER2– Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses remaining questions and unmet needs following the FDA approval of capivasertib in combination with fulvestrant in hormone receptor–positive, HER2-negative breast cancer.

Related Keywords

Adamm Brufsky , ,University Of Pittsburgh School Medicine ,Breast Cancer Center ,Division Of Hematology Oncology ,Department Of Medicine ,Women Cancer Program ,Hillman Cancer Center ,Pittsburgh School ,Cancer Program ,Comprehensive Breast Cancer Center ,Cancer Center ,Upmc Hillman Cancer Center ,Onclive Tv ,Breast Cancer ,